Investigating side effects of a new tuberculosis prevention treatment in Uganda
Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy
['FUNDING_R01'] · INFECTIOUS DISEASES INSTITUTE · NIH-11142468
This study is looking at how safe a new tuberculosis prevention treatment is for adults and kids in Uganda, and it will help us understand who might have side effects while taking it, so we can make sure more people can complete their treatment successfully.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INFECTIOUS DISEASES INSTITUTE (nih funded) |
| Locations | 1 site (KAMPALA, UGANDA) |
| Trial ID | NIH-11142468 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the safety and side effects of a new tuberculosis prevention treatment called rifapentine combined with isoniazid, which is being rolled out in Uganda. The study will involve enrolling 614 adults and children who will receive this treatment, and they will be monitored for any adverse drug reactions over several months. By identifying which patients are more likely to experience side effects, the research aims to improve treatment completion rates and overall tuberculosis control. Participants will undergo regular evaluations, including questionnaires and laboratory tests, to assess their health during the treatment period.
Who could benefit from this research
Good fit: Ideal candidates include adults and children over 2 years old who are starting tuberculosis preventive therapy with rifapentine and isoniazid.
Not a fit: Patients who are not starting this specific tuberculosis prevention treatment or those with contraindications to rifapentine or isoniazid may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer tuberculosis prevention strategies and improved health outcomes for patients receiving treatment.
How similar studies have performed: Previous research has shown that similar approaches to monitoring drug safety in tuberculosis treatments can yield valuable insights, although this specific combination is being evaluated in a new context.
Where this research is happening
KAMPALA, UGANDA
- INFECTIOUS DISEASES INSTITUTE — KAMPALA, UGANDA (ACTIVE)
Researchers
- Principal investigator: SEKAGGYA-WILTSHIRE, CHRISTINE — INFECTIOUS DISEASES INSTITUTE
- Study coordinator: SEKAGGYA-WILTSHIRE, CHRISTINE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Syndrome Virus